ASCO Annual Meeting | Conference

Dr. Abou-Alfa on Efficacy With Ivosidenib in IDH1+ Cholangiocarcinoma

June 7th 2021

Ghassan K. Abou-Alfa, MD, discusses the efficacy of ivosidenib in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study.

Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

June 7th 2021

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL

June 7th 2021

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

mFOLFOXIRI/Cetuximab Combo Improves Depth of Response in RAS Wild-Type mCRC

June 7th 2021

Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

June 7th 2021

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

June 7th 2021

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 7th 2021

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Sacituzumab Govitecan Maintains Efficacy Benefit Over Chemo in Metastatic TNBC, Irrespective of Agent

June 7th 2021

The antibody-drug conjugate sacituzumab govitecan retained benefit in progression-free survival, overall survival, and objective response rate over physician’s choice of therapy, regardless of the chemotherapy agent used.

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

June 7th 2021

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.

HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC

June 7th 2021

Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.

SD-101 Plus Pembrolizumab and Paclitaxel Yields Moderate Response Boost in High-Risk, HER2-Negative Breast Cancer

June 7th 2021

Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer

June 7th 2021

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Acalabrutinib is Better Tolerated, Noninferior to Ibrutinib in Previously Treated CLL

June 7th 2021

Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer

June 7th 2021

Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.

Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors

June 7th 2021

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma

June 6th 2021

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma

June 6th 2021

Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.

Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up

June 6th 2021

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors

June 6th 2021

Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.

Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant Medullary Thyroid Cancer

June 6th 2021

Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy.